[Ranibizumab as a treatment for type 2 non-proliferative macular telangiectasia]

J Fr Ophtalmol. 2016 Jan;39(1):e9-e11. doi: 10.1016/j.jfo.2014.08.016. Epub 2015 Nov 12.

[Article in French]

Authors

Y Troumani¹, M M'garrech², S Touhami², S Hayek², E Barreau², L Bonin², A Rousseau², M Labetoulle²

Affiliations

¹ Service d'ophtalmologie, centre hospitalier universitaire, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France. Electronic address: y.troumani@gmail.com.
² Service d'ophtalmologie, centre hospitalier universitaire, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France.

PMID: 26584774
DOI: 10.1016/j.jfo.2014.08.016

No abstract available

Publication types

Letter

MeSH terms

Aged
Diagnostic Techniques, Ophthalmological
Humans
Intravitreal Injections
Male
Ranibizumab / administration & dosage
Ranibizumab / therapeutic use*
Retinal Telangiectasis / diagnosis
Retinal Telangiectasis / drug therapy*
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

VEGFA protein, human
Vascular Endothelial Growth Factor A
Ranibizumab